Liraglutide (Saxenda, Victoza)
Liraglutide is the older GLP-1 medication, injected every day and sold as Saxenda for weight and Victoza for type 2 diabetes. It produces less weight loss than the weekly drugs, and in 2025 it became the first GLP-1 with an FDA-approved generic for weight loss.
- Legal lane: FDA-approved, prescription only
- Evidence grade: A
- Form: daily injection under the skin, from a prefilled pen
- Brands: Saxenda (weight), Victoza (type 2 diabetes), and generics of both
What it is
Liraglutide acts on the same GLP-1 receptor as semaglutide, but it is cleared faster and has to be injected daily. The FDA approved Saxenda for chronic weight management in adults in December 2014 and extended it to adolescents aged 12 to 17 in December 2020.
What the evidence shows
The main trial, SCALE Obesity and Prediabetes, followed 3,731 adults for 56 weeks. Average weight loss was 8.0% on liraglutide 3 mg against 2.6% on placebo. About 63% of people on liraglutide lost at least 5% of their weight, against 27% on placebo.
That is a real effect and a smaller one than the weekly drugs produced in their own trials. The trials were separate, so the comparison is indirect.
Legal status
- FDA-approved as Saxenda for chronic weight management, with a reduced-calorie diet and more physical activity, in adults with obesity or with overweight and a weight-related condition, and in some adolescents.
- FDA-approved as Victoza for type 2 diabetes.
- Generics: a generic of Victoza launched in June 2024. On August 27, 2025, the FDA approved a generic of Saxenda, the first generic GLP-1 approved for weight loss in the US.
Label dosing
The Saxenda label starts at 0.6 mg a day for one week and raises the dose by 0.6 mg each week, through 1.2 mg, 1.8 mg and 2.4 mg, to 3 mg a day. The slow increase is there to reduce stomach side effects.
The label says to check progress at 16 weeks and stop if a patient has not lost at least 4% of their starting weight. The dose on your prescription is the one to follow.
Safety
- Boxed warning: thyroid C-cell tumors seen in rodents. It should not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2.
- Stomach side effects: nausea is the most common, especially while the dose is rising.
- Gallbladder: gallbladder disease was more common on Saxenda than placebo in trials.
- Injection sites: the label says to rotate sites.
On any GLP-1, some of the weight lost is muscle. See protein and muscle on GLP-1s.
Common questions
How is liraglutide different from semaglutide?
It acts on the same receptor but is injected every day, not every week, and its main trial showed less weight loss.
How much weight do people lose on Saxenda?
In its main trial, an average of 8.0% of body weight over 56 weeks, against 2.6% on placebo.
Is there a generic Saxenda?
Yes. The FDA approved a generic of Saxenda on August 27, 2025.
What is the Saxenda dose schedule?
The label starts at 0.6 mg a day and rises by 0.6 mg each week to 3 mg a day.
Ask an AI about this page
Opens the assistant with a question about this page already typed in. You can edit it before sending.
Ask ChatGPTAsk ClaudeAsk Perplexity
These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.
Sources
- Saxenda prescribing information (dose schedule, boxed warning, 16-week check)
- Novo Nordisk: Saxenda dosing and the 16-week assessment
- Pi-Sunyer et al., 2015: SCALE Obesity and Prediabetes trial, NEJM (PubMed)
- Patient Care: first generic of Saxenda approved (August 2025)
- Healio: generic Saxenda approval and the 2024 Victoza generic
Taking a prescribed GLP-1? Keep a private record of shots, weight and protein with the dose and progress log.